ArticleOpen medicine (Warsaw, Poland)2026
Identification of age-specific urinary metabolic biomarkers in Wilson disease using machine learning: a comparative study of ensemble tree models.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The diagnosis of Wilson disease (WD) is complicated by heterogeneous clinical phenotypes and inadequate performance of routine biomarkers. This study sought to screen age-specific urinary metabolic biomarkers to assist WD diagnosis via ensemble tree-based machine learning algorithms. Methods: Sixty participants were enrolled, comprising 30 WD patients (10 pediatric, 20 adult) and 30 healthy controls. Morning urine samples were analyzed using UPLC-Q-TOF-MS in both ionization modes. Orthogonal partial least squares discriminant analysis identified differential metabolites. Four ensemble algorithms (Random Forest, GBDT, XGBoost, LightGBM) were compared using nested cross-validation to minimize overfitting risk. LASSO regression selected optimal metabolite panels. Model performance was evaluated using 5-fold cross-validation with AUC as the primary metric. Results: XGBoost achieved AUC values of 0.87±0.03 (pediatric) and 0.96±0.02 (adult) in nested validation, with permutation testing confirming performance above chance levels (p>0.001). Sixty-eight differential metabolites were identified in pediatric patients versus 109 in adults, with 15 metabolites consistently altered across both age groups. Pathway analysis revealed age-specific disruptions: nucleotide metabolism in pediatric patients and oxidative stress pathways in adults. LASSO feature selection identified 7 metabolites for pediatric and 3 for adult classification while maintaining high diagnostic accuracy. Conclusions: This study successfully developed the first age-specific metabolomics-based diagnostic approach for WD using ensemble machine learning. The distinct metabolic signatures between age groups provide mechanistic insights into WD pathophysiology and support personalized diagnostic strategies for improved patient outcomes. These exploratory findings require independent validation before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.